產(chǎn)品編號：Y0744

英文名稱：Retinoic acid

CAS號 302-79-4

分析標(biāo)準(zhǔn)品

分子式 C20H28O2 分子量300.44

基本信息:

密度1.011

熔點(diǎn)180-181°C

存貯條件儲存溫度：-20°C

描述

產(chǎn)品介紹不溶于水，溶于乙醚、DMSO (25 mg/ml)；微溶于乙醇和氯仿。

別名維生素A酸 ;維A酸;all-trans-Retinoic acid ATRA Tretinoin Vitamin A acid

生化機(jī)理

Description: IC50 Value: N/A All-trans retinoic acid (ATRA) has been widely investigated for treatments of many cancers including prostate cancer. in vitro: ATRA was able to induce the growth arrest and to increase HOXB13 expression in ARprostate cancer cells. Both EZH2 and DNMT3b participated in the repression of HOXB13 expression through an epigenetic mechanism involving DNA and histone methylation modifications[1]. ATRA could upregulate HOXB13 through decreasing EZH2 and DNMT3b expressions and reducing their interactions with the HOXB13 promoter[1]. in vivo: Earlier studies revealed that treatment of leukemic cells with ATRA resulted in the apoptosis, presumably secondary to the differentiation process. Since ATRA can rectify aberrant cell growth and induce apoptosis, it has been widely investigated in preclinical and clinical trials for the treatment of many cancer types, including early gastric cancer and prostate cancer . In AR and drug resistant DU145 prostate cancer cells, ATRA was demonstrated to increase the sensitivity of cells to anticancer agent docetaxel[1]. All-trans retinoic acid (ATRA) induces clinical remission in APL patients by enhancing the rapid differentiation of APL cells and the clearance of PML-RARα, APL's hallmark oncoprotein[2]. Clinical trial: N/A

應(yīng)用維生素A酸(ATRA) 是一種維生素A酸受體(RAR)和Retinoid X 受體(RXR)的配體，結(jié)合上RAR 和 RXR作為轉(zhuǎn)導(dǎo)因子，調(diào)控正常細(xì)胞和腫瘤細(xì)胞的生長和分化。細(xì)胞色素P450 (CYPs) 催化ATRA的羥基化；維生素A酸引導(dǎo)胚胎干細(xì)胞(embryonic stem cells) 演變成神經(jīng)元。